Chinese aspirin
This article was originally published in The Tan Sheet
Executive Summary
Antidumping margin of 144% applicable to all but two bulk aspirin exporters in the People's Republic of China, the International Trade Administration says in a final determination published in the Federal Register May 25. ITA assigns weighted-average dumping margins of 42.8% to Shandong Xinhau Pharmaceutical Factory and 4.7% to Jilin Pharmaceutical. The case now goes to the International Trade Commission, which will issue an antidumping order if it determines Chinese bulk aspirin imports are materially injurious, or threaten material injury, to U.S. industry. The investigation was requested by Cranbury, N.J.-based bulk aspirin maker Rhodia (1"The Tan Sheet" June 14, 1999, p. 9)
You may also be interested in...
Aspirin dumping
U.S. Customs service will impose antidumping duties on bulk aspirin imports from China following a June 22 ITC determination the imports threaten U.S. industry with material injury. In an amended final determination June 21, the ITA revises previously announced weighted-average dumping margins for two Chinese firms: Shandong Xinhua Pharmaceutical Factory, 16.5% (previously 42.8%) and Jilin Pharmaceutical, 10.9% (previously 4.7%). The PRC-wide rate of 144% is unchanged (1"The Tan Sheet" May 29, In Brief)
Chinese Aspirin "Dumping" Is Under Trade Commission Investigation
The International Trade Commission is instituting an investigation into evidence of possible Chinese aspirin "dumping" onto the U.S. market, the commission announced in the Federal Register June 7. The investigation follows a May 28 petition from bulk aspirin manufacturer Rhodia requesting the "imposition of antidumping duties on imports of bulk aspirin from the People's Republic of China."
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC